News

Kurin, Inc. announces results on Kurin® efficacy from Oishei Children’s Hospital with zero blood culture contaminations

Kurin, Inc. Announces Removal of Magnolia Patent Infringement Lawsuit Trial Date

Kurin, Inc. announces peer-reviewed publication on Kurin® efficacy from Central Texas Veterans Health Care System

Kurin, Inc. honored by MD Tech Review in annual listing of top Infection Control solutions

Kurin, Inc. Named to Inc.’s Inaugural Best in Business List in the Prosperous and Thriving Category

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office of Additional Claims to its Innovative Blood Culture Collection Device.

Kurin, Inc. Reports Record Revenues

Kurin, Inc. Receives Supplier Horizon Award from Premier Inc.

Kurin, Inc. continues sales growth with record month.

Kurin, Inc. Announces Agreement with Intalere for Kurin Lock to impact contaminated blood cultures

Kurin, Inc. Announces Agreement with Vizient for Kurin Lock to help reduce contaminated blood cultures

Kurin, Inc. receives FDA 510k clearance for its push-button needle

Kurin, Inc. Announces Hire of EVP Operations Amid Record Growth

Kurin, Inc. Reports Record Third Quarter Revenues

Kurin, Inc. receives CE Mark for its novel Kurin Lock®

Kurin Inc. Responds to Allegations Published by Magnolia Medical Regarding Patent Infringement

Kurin, Inc. CEO Addresses Patent Infringement Lawsuit Brought by Magnolia Medical

Kurin, Inc. receives FDA 510k clearance for its novel Kurin Lock with peripheral IV infusion set.

Kurin, Inc. announces clinical results on Kurin® efficacy from Central Texas Veterans Health Care System

Kurin, Inc. Announces Agreement with Premier for Kurin Lock® to help impact contaminated blood cultures

1 2

ML-021 Rev A